

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07C 275/64, A61K 31/17		A1	(11) International Publication Number: WO 99/28291 (43) International Publication Date: 10 June 1999 (10.06.99)
(21) International Application Number: PCT/US98/25163			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 24 November 1998 (24.11.98)			
(30) Priority Data: 08/984,477 3 December 1997 (03.12.97) US			Published <i>With international search report.</i>
(71) Applicant: MINNESOTA MINING AND MANUFACTURING COMPANY [US/US]; 3M Center, P.O. Box 33427, Saint Paul, MN 55133-3427 (US).			
(72) Inventor: MERILL, Bryon, A.; P.O. Box 33427, Saint Paul, MN 55133-3427 (US).			
(74) Agents: HOWARD, MarySusan et al.; Minnesota Mining and Manufacturing Company, Office of Intellectual Property Counsel, P.O. Box 33427, Saint Paul, MN 55133-3427 (US).			

(54) Title: BISHYDROXYUREAS AS INHIBITORS OF THE 5-LIPOXYGENASE



(57) Abstract

Bishydroxyureas are provided that inhibit the enzyme 5-lipoxygenase. These compounds have formula (I) wherein R₁, R₂, R₃, R₄, A and M are defined herein. Also disclosed are pharmaceutical compositions containing such compounds and methods of inhibiting the enzyme 5-lipoxygenase using such compounds.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

BISHYDROXYUREAS AS INHIBITORS OF THE 5-LIPOXYGENASE

5 Field of the Invention

This invention relates to bishydroxyurea compounds that are useful to inhibit the 5-lipoxygenase mediated metabolism of arachidonic acid. In another aspect this invention relates to pharmaceutical compositions comprising bishydroxyureas. A further aspect of this invention relates to methods of treating diseases mediated by products of the 5-lipoxygenase pathway in a subject in need thereof by administering a bishydroxyurea compound to the subject.

10 Background of the Invention

An important biosynthetic pathway for the metabolism of arachidonic acid is initiated by the enzyme 5-lipoxygenase (5-LO). The first product formed by the oxidation of arachidonic acid with 5-LO is 5-hydroperoxyeicosatetraenoic acid (5-HPETE) which is subsequently converted to either 5-hydroxyeicosatetraenoic acid (5-HETE) or the leukotriene intermediate LTA4. Further enzymatic metabolism of LTA4 leads to the production of LTB4 and the peptidoleukotrienes (LTC4, LTD4, and LTE4).

15 The above mentioned biosynthetic products of the 5-LO pathway are very potent substances. When present in the nanomolar to picomolar concentration range, these compounds produce a variety of biological effects which are associated with mammalian disease. For example, 5-HETE stimulates tumor growth in epithelial and squamous cell based cancers. The peptidoleukotrienes are known to be potent constrictors of human airway smooth muscle; aerosol administration of these substances to non-asthmatic volunteers has been shown to induce bronchoconstriction. Both LTB4 and 5-HETE are potent chemotactic factors for inflammatory cells such as polymorphonuclear leukocytes, and both compounds have been isolated in the synovial fluids of arthritic patients.


20 Disease states in which leukotrienes are important mediators include: adult respiratory distress syndrome, allergic rhinitis, arthritis, asthma, chronic obstructive

pulmonary disease, gout, inflammatory bowel disease, ischemic induced myocardial injury, psoriasis, reperfusion injury, spinal cord injury, stroke, and traumatic brain injury.

A chemical compound which acts as an inhibitor of the 5-LO enzyme should be an effective therapeutic agent for the treatment or prevention of these diseases, as well as any 5 other disease which is mediated by products of the 5-LO pathway.

Summary of the Invention

Certain bishydroxyurea compounds have been found that inhibit 5-lipoxygenase (5-LO). These compounds are useful in the treatment of disease states that are mediated 10 by products of the 5-LO pathway, including leukotrienes and 5-HETE. Accordingly, the invention provides compounds of Formula I:



I


15

wherein R₁, R₂, R₃, R₄, A and M are defined below.

The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I and a pharmaceutically acceptable vehicle. Further, this invention provides a method of inhibiting the enzyme 5-20 lipoxygenase in an animal and a method of treating an animal having a condition responsive to such inhibition, comprising administering to the animal a compound of Formula I in an amount effective to inhibit 5-lipoxygenase.

Detailed Description of the Invention

25 The bishydroxyurea compounds of this invention are compounds of Formula I



I

wherein R_1 , R_2 , R_3 , R_4 , A and M have the following meanings:

5 R_1 and R_2 are independently selected from the group consisting of hydrogen and C_{1-6} straight or branched chain alkyl. Preferably R_1 and R_2 are the same. More preferably, R_1 and R_2 are hydrogen.

10 R_3 and R_4 are independently selected from the group consisting of C_{1-14} straight or branched chain alkyl optionally substituted by a group selected from halogen, nitro, hydroxyl, carboxyl and amino, and optionally interrupted by $-\text{O}-$, $-\text{S}(\text{O})_{0-2}-$, $-\text{NR}-$ wherein 15 R is as defined below, or $-\text{CO}-$; and arylalkyl wherein the alkyl group is straight or branched chain and has from one to eight carbon atoms and the aryl group is phenyl optionally substituted with one or more substituents selected from the group consisting of C_{1-6} straight or branched chain alkyl and halogen. Preferably R_3 and R_4 are the same and are selected from the group consisting of C_{1-6} straight or branched chain alkyl and phenylalkyl wherein the alkyl group is straight or branched chain and has from one to eight carbon atoms. More preferably R_3 and R_4 are the same and are selected from the group consisting of methyl, isopropyl, 1-ethylpropyl and benzyl.

A is selected from the group consisting of:


20 (a) phenylene optionally substituted with one or more substituents selected from the group consisting of C_{1-6} straight or branched chain alkyl and halogen;

(b) C_{3-8} cycloalkylene;

(c) C_{1-12} straight or branched chain alkylene;


(d) naphthalene optionally substituted with one or more substituents selected from 25 the group consisting of C_{1-6} straight or branched chain alkyl and halogen;

(e)



wherein each R₅ and R₆ is independently selected from the group consisting of hydrogen and C₁₋₃ straight or branched chain alkyl; and

5 (f)



wherein each R₇ and R₈ is independently selected from the group consisting of hydrogen, C₁₋₃ straight or branched chain alkyl, C₁₋₃ alkoxy, and halogen;

10 m is 1 or 2;

n is 1 or 2; and

B is selected from the group consisting of

(i) a carbon-carbon bond;


(ii) oxy;

15 (iii) thio;

(iv) sulfone;

(v) carbonyl;


(vi)



20 wherein R is selected from the group consisting of hydrogen and C₁₋₃ straight or branched chain alkyl;

(vii) —(CH₂)_p— wherein p is an integer from 1 to 14; and


(viii)




wherein R_9 and R_{10} are independently selected from the group consisting of hydrogen, C_{1-3} straight or branched chain alkyl, C_{3-6} cycloalkyl, and trifluoromethyl.

5 Preferably A is selected from the group consisting of

- (a) C_{1-12} straight or branched chain alkylene and
- (b)



10 When A is




15 the urea groups are preferably bonded at the para position of each ring. Preferably R_7 and R_8 are the same and are selected from the group consisting of hydrogen, C_{1-3} straight or branched chain alkoxy and chloro and m and n are both 1. More preferably R_7 and R_8 are hydrogen or chloro.


Preferably B is selected from the group consisting of:

- (a) a carbon-carbon bond;
- 20 (b) oxy; and

(c)



When B is



5

preferably R_9 and R_{10} are the same and are selected from the group consisting of hydrogen and trifluoromethyl. More preferably B is methylene or oxy.

M is selected from the group consisting of hydrogen, a pharmaceutically acceptable cation, and a pharmaceutically acceptable metabolically cleavable group.

Preferably, M is hydrogen.


The term "pharmaceutically acceptable cation" refers to nontoxic cations well known to those skilled in the art and including but not limited to those based on the alkali and alkaline earth metals such as sodium, lithium, potassium, magnesium, aluminum and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations derived from nitrogenous bases of sufficient basicity to form salts with the N-hydroxy group of compounds of Formula I where M is hydrogen.

The term "metabolically cleavable group" denotes a moiety that is readily cleaved in vivo from the compound bearing it. The compound remains or becomes pharmacologically active after cleavage. Metabolically cleavable groups are generally derived from compounds known to those skilled in the art that are reactive with the N-hydroxy group of compounds of Formula I where M is hydrogen. Such groups include, but are not limited to, alkanoyl such as acetyl, propionyl, and the like, unsubstituted and substituted aroyl such as benzoyl and substituted benzoyl, alkoxy carbonyl such as ethoxycarbonyl and the like, monoesters formed from dicarboxylic acids such as succinyl, unsubstituted and substituted carbamoyl such as dimethylcarbamoyl and so on.

Compounds bearing metabolically cleavable groups can act as prodrugs and may exhibit improved bioavailability over the parent compound.

The invention is inclusive of compounds that can exist in multiple isomeric forms. These individual forms, including enantiomers and diastereomers as well as mixtures of 5 the various forms, are part of the invention.

Preferred compounds include compounds of Formula II:



10


wherein R', R" and B are as defined below.

R' is selected from the group consisting of C₁₋₁₄ straight or branched chain alkyl and benzyl. Preferred R' groups include methyl, isopropyl, 1-ethylpropyl and benzyl.

15 R" is selected from the group consisting of hydrogen, C₁₋₃ straight or branched chain alkyl, halogen, and C₁₋₃ straight or branched chain alkoxy. Preferably R" is hydrogen or chloro.

B is selected from the group consisting of:

- (a) a carbon-carbon bond;
- (b) oxy; and
- 20 (c)



wherein R₉ and R₁₀ are the same and are selected from the group consisting of hydrogen and trifluoromethyl. B is preferably oxy or methylene.

25 Preferred compounds of the invention include:


4,4'-Methylenebis(1-hydroxy-1-isopropyl-3-phenylurea);
4,4'-Methylenebis(1-hydroxy-1-benzyl-3-phenylurea);
4,4'-Methylenebis(1-hydroxy-1-methyl-3-(2,6-diethylphenyl)urea);
4,4'-Oxybis(1-hydroxy-1-methyl-3-phenylurea);
5 1,1'-(m-Phenylene)bis(3-hydroxy-3-methylurea);
1,1'-(1,5-Naphthalene)bis(3-hydroxy-3-methylurea);
trans-1,4-Cyclohexanebis(3-hydroxy-3-methylurea);
1,1'-Hexamethylenebis(3-hydroxy-3-benzylurea);
1,1'-(4,4'-(2,2'-Dimethoxy)biphenyl)bis(3-hydroxy-3-methylurea);
10 1,1'-(m-Phenylene)bis(1-methyl-1-(3-hydroxy-3-(1-ethylpropyl)ureido)ethane);
1,1'-(p-Phenylene)bis(3-hydroxy-3-(1-ethylpropyl)urea);
1,1'-(4-Methyl-m-phenylene)bis(3-hydroxy-3-(1-ethylpropyl)urea);
1,1'-(2-Methylpentamethylene)bis(3-hydroxy-3-(1-ethylpropyl)urea); and
1,1'-Octamethylenebis(3-hydroxy-3-(1-ethylpropyl)urea).

15 Particularly preferred compounds of the invention include:

4,4'-Methylenebis(1-hydroxy-1-methyl-3-phenylurea);
4,4'-(2,2-Hexafluoropropane)bis(1-hydroxy-1-methyl-3-phenylurea);
4,4'-Methylenebis(1-hydroxy-1-(1-ethylpropyl)-3-phenylurea); and
4,4'-Oxybis(1-hydroxy-1-(1-ethylpropyl)-3-phenylurea); and
20 4,4'-Methylenebis(1-hydroxy-1-(1-ethylpropyl)-3-(2-chlorophenyl)urea).

Compounds of the invention can be prepared in accordance with the Reaction Schemes described below or through modifications thereof that will be readily apparent to those skilled in the art. A suitable route can be selected with due consideration of the particular R_1 , R_2 , R_3 , R_4 , A and M substituents, availability of starting materials and the like.

Compounds of the invention where R_1 , R_2 and M are all hydrogen and R_3 and A are as defined above can be prepared according to Reaction Scheme I.

Reaction Scheme I

5

Reaction Scheme I involves reacting a hydroxylamine of Formula III with a diisocyanate of Formula IV to provide a bishydroxyurea of Formula V. Many hydroxylamines of Formula III are commercially available. Others may be readily prepared using conventional methods, for example, by conversion of a suitable aldehyde 10 or ketone to its oxime followed by reduction to the hydroxylamine. Many diisocyanates of Formula IV are also commercially available. Others may readily be prepared using conventional methods, for example, Curtius rearrangement, Hofmann rearrangement, Schmidt reaction, or by reacting a suitable diamine with phosgene or a phosgene equivalent (e.g. 1,1'-carbonyldiimidazole or 1,1'-carbonylbisbenzotriazole). The reaction 15 in Reaction Scheme I can be conducted at ambient temperature by combining the hydroxylamine and the diisocyanate in a suitable solvent (e.g. an organic solvent such as diethyl ether, tetrahydrofuran, dichloromethane). When a salt (e.g. hydrochloride) of the hydroxylamine is used, it is converted to the free base using conventional means (e.g. reacting with one equivalent of base in a suitable solvent) prior to its reaction with the 20 diisocyanate.

The compounds of Formula I wherein M is a pharmaceutically acceptable cation can be prepared by combining a compound of Formula I wherein M is hydrogen with a relatively strong base, e.g., a base of the formula $M(OH)_x$ wherein M is the pharmaceutically acceptable cation and x is the valence of such cation in a polar solvent.


5 Isolation of the salt can be facilitated by the addition of a solvent in which the salt is insoluble.

Compounds of Formula I in which R_3 and R_4 are different can be prepared by reacting one mole of a diisocyanate of Formula IV sequentially with one mole of a hydroxylamine of formula R_3NHOH and one mole of a hydroxylamine of formula R_4NHOH and isolating the desired bishydroxyurea from the resulting mixture using conventional separation techniques (e.g., flash chromatography, selective recrystallization).

Compounds of Formula I in which R_1 and R_2 are other than hydrogen and R_3 and R_4 are the same can be prepared by the reaction of one mole of a diamine with two moles 15 of phosgene or a phosgene equivalent (e.g. 1,1'-carbonyldiimidazole or 1,1'-carbonylbisbenzotriazole) followed by two moles of a hydroxylamine of the formula R_3NHOH .

Compounds of Formula I in which R_1 , R_2 , R_3 , R_4 , R_7 and R_8 are as defined above and A is

20



can be prepared by palladium catalyzed coupling of appropriately functionalized hydroxyurea precursors when B is a carbon-carbon bond or methylene (such as the Stille 25 or Suzuki coupling reactions); and can be prepared by copper catalyzed coupling of appropriately functionalized hydroxyurea precursors when B is oxy (such as the Ullmann Reaction).

A compound of Formula I can be formulated for various routes of administration (e.g. oral, topical, parenteral) in an appropriate pharmaceutically acceptable vehicle suitable for the selected dosage form. Suitable excipients and preparation of pharmaceutical compositions are well known to those skilled in the art and disclosed, e.g. 5 in *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Mack Publishing Company.


A pharmaceutical composition of the invention comprises a therapeutically effective amount of a compound of Formula I. The amount that constitutes a therapeutically effective amount will depend on the particular compound, the particular formulation, the route of administration, and the intended therapeutic effect. Those skilled 10 in the art can readily determine a therapeutically effective amount with due consideration of such factors.

Compounds of Formula I have been shown to inhibit the enzyme 5-lipoxygenase, and therefore have utility in treating conditions mediated by products of the 5-lipoxygenase pathway. Such conditions include but are not limited to adult respiratory 15 distress syndrome, allergic rhinitis, arthritis, asthma, cancer, chronic obstructive pulmonary disease, gout, inflammatory bowel disease, ischemic induced myocardial injury, psoriasis, reperfusion injury, spinal cord injury, stroke, and traumatic brain injury.

The examples below are given to further illustrate the invention. The particular materials used and amounts thereof, as well as other conditions and details, should not be 20 construed to limit the invention.

Example 1

4,4'-Methylenebis(1-hydroxy-1-methyl-3-phenylurea)




5

A mixture of N-methylhydroxylamine-hydrochloride (2.5 g, 30 mmol), water (5 ml), and diethyl ether (100 ml) was cooled to 0 °C and NaOH (1.3 g dissolved in 10 ml of water) was added dropwise over a 10 min period. The mixture was maintained at 0 °C for 10 min followed by the addition of 4,4'-methylenebis(phenylisocyanate) (2.5 g, 10 mmol) as a solid. A white precipitate formed immediately. After 0.5 h, the cooling bath was removed and the reaction was maintained at ambient temperature for 15 h. The reaction was filtered to provide a white powder. Recrystallization from N,N-dimethylformamide\water yielded 2.0 g of the desired product as white plates: MP: 196.0 °C (decomp); 1H NMR (300 MHz, DMSO): δ 9.70 (s, 2H), 8.86 (s, 2H), 7.48 (d, J =8.5 Hz, 4H), 7.06 (d, J =8.5 Hz, 4H), 3.78 (s, 2H), 3.04 (s, 6H); 13C NMR (75 MHz, DMSO): δ 157.9, 137.2, 135.2, 128.3, 119.3, 39.9, 38.1; MS (FAB): m/e 345.1560 (345.1563 calc'd for C₁₇H₂₁N₄O₄, M+H); Anal. calc'd for C₁₇H₂₀N₄O₄: C, 59.29; H, 5.85; N, 16.27. Found: C, 59.30; H, 5.82; N, 16.36.

20

Example 2

4,4'-Methylenebis(1-hydroxy-1-isopropyl-3-phenylurea)



25


The same general procedure as reported in Example 1 was followed. 4,4'-Methylenebis(phenylisocyanate) (2.0 g, 8 mmol), N-isopropylhydroxylamine-hydrochloride (2.7 g, 24 mmol), NaOH (1.1 g dissolved in 10 ml of water), diethyl ether

(100 ml), and water (5 ml) were combined. Filtration of the reaction mixture yielded 2.9 g of the desired product as a white powder. Recrystallization from N,N-dimethylformamide\water provided an analytically pure sample: MP: 219.0 °C (decomp); 1H NMR (300 MHz, DMSO): δ 9.24 (s, 2H), 8.82 (s, 2H), 7.50 (d, J=8.5 Hz, 4H), 7.06 (d, 5 J=8.5 Hz, 4H), 4.30 (septet, J=6.6 Hz, 2H), 3.78 (s, 2H) 1.06 (d, J=6.6 Hz, 12H); 13C NMR (75 MHz, DMSO): δ 156.9, 136.7, 134.7, 127.8, 118.7, 47.9, 39.4, 18.1; MS (FAB): m/e 401.2189 (401.2189 calc'd for C₂₁H₂₉N₄O₄, M+H); Anal. calc'd for C₂₁H₂₈N₄O₄: C, 62.98; H, 7.05; N, 13.99. Found: C, 63.04; H, 6.96; N, 13.85.

10

Example 3

4,4'-Methylenebis(1-hydroxy-1-benzyl-3-phenylurea)




15

The same general procedure as reported in Example 1 was followed. 4,4'-Methylenebis(phenylisocyanate) (2.0 g, 8 mmol), N-benzylhydroxylamine-hydrochloride (3.9 g, 24 mmol), NaOH (1.1 g dissolved in 10 ml of water), diethyl ether (100 ml), and water (5 ml) were combined. Filtration of the reaction mixture yielded 3.7 g of the desired product as a pale tan powder. Recrystallization from N,N-dimethylformamide\water provided an analytically pure sample: MP: 189.0 °C (decomp); 1H NMR (300 MHz, DMSO): δ 9.90 (s, 2H), 8.92 (s, 2H), 7.52 (d, J=8.6 Hz, 4H), 7.33-7.21 (m, 10 H), 7.08 (d, 20 J=8.6 Hz, 4H), 4.63 (s, 4H), 3.79 (s, 2H); 13C NMR (75 MHz, DMSO): δ 157.2, 137.6, 137.2, 135.2, 128.3, 128.0, 126.8, 119.3, 53.2, 39.9; IR (KBr): 3379, 3062, 2919, 2852, 1621, 1595, 1549, 1419, 1226, 1089, 775, 696 cm⁻¹; MS (FAB): m/e 497.2206 (497.2188 calc'd for C₂₉H₂₉N₄O₄, M+H); Anal. calc'd for C₂₉H₂₈N₄O₄: C, 70.15; H, 5.68; N, 11.28. Found: C, 70.23; H, 5.63; N, 11.28.

Example 4

4,4'-Methylenebis(1-hydroxy-1-methyl-3-(2,6-diethylphenyl)urea)



5


The same general procedure as reported in Example 1 was followed. 4,4'-Methylenebis(2,6-diethylphenylisocyanate) (3.6 g, 10 mmol), N-methylhydroxylamine-hydrochloride (2.5 g, 30 mmol), NaOH (1.3 g dissolved in 15 ml of water), diethyl ether (100 ml), and water (5 ml) were combined. The product formed as a precipitate.

10 Recrystallization from N,N-dimethylformamide\water provided 1.8 g of the desired product as a white powder: MP: 257.0 °C (decomp); ¹H NMR (300 MHz, DMSO): δ 9.61 (s, 2H), 8.16 (s, 2H), 6.93 (s, 4H), 3.83 (s, 2H), 3.00 (s, 6H), 2.50-2.43 (q, J= 7.5 Hz, 8H), 1.09-1.04 (t, J=7.5 Hz, 12H); IR (Nujol): 3409, 1623, 1603, 1526, 1395, 1342, 1182, 1119 cm⁻¹; MS (FAB): m/e 457.2828 (457.2815 calc'd for C₂₅H₃₇N₄O₄, M+H); Anal.

15 calc'd for C₂₅H₃₆N₄O₄: C, 65.76; H, 7.95; N, 12.27. Found: C, 65.62; H, 7.99; N, 12.31.

Example 5

4,4'-(2,2-Hexafluoropropane)bis(1-hydroxy-1-methyl-3-phenylurea)




20

The same general procedure as reported in Example 1 was followed. 2,2-Bis(4-isocyanatophenyl)hexafluoropropane (2.0 g (5.2 mmol) dissolved in 25 ml of diethyl ether), N-methylhydroxylamine-hydrochloride (1.3 g, 15.5 mmol), NaOH (0.7 g dissolved in 10 ml of water), diethyl ether (50 ml), and water (5 ml) were combined. The product formed as a precipitate. Recrystallization from N,N-dimethylformamide\water provided

0.72 g of the desired product as a fine white powder: MP: 182.0 °C (decomp); ¹H NMR (300 MHz, DMSO): δ 9.90 (broad s, 2H), 9.30 (broad s, 2H), 7.70 (d, J=8.8 Hz, 4H), 7.19 (d, J=8.8 Hz, 4H), 3.08 (s, 6H); ¹³C NMR (75 MHz, DMSO): δ 157.2, 140.1, 129.4, 125.1, 124.6 (q, J=284 Hz), 118.5, 37.6; IR (KBr): 3332, 3047, 2822, 1598, 1550, 1422, 1364, 1248, 1177, 968, 957, 930, 835, 827 cm⁻¹; MS (FAB): m/e 481.1317 (481.1310 calc'd for C₁₉H₁₉N₄O₄F₆, M+H); Anal. calc'd for C₁₉H₁₈N₄O₄F₆: C, 47.51; H, 3.78; N, 11.66. Found: C, 47.45; H, 3.68; N, 11.88.

Example 6


10 4,4'-Oxybis(1-hydroxy-1-methyl-3-phenylurea)



The same general procedure as reported in Example 1 was followed. 4,4'-oxybis(phenylisocyanate) (2.36 g, 10 mmol), N-methylhydroxylamine-hydrochloride (2.5 g, 30 mmol), NaOH (1.3 g dissolved in 10 ml of water), diethyl ether (100 ml), and water (5 ml) were combined. The product formed as a precipitate. Recrystallization from N,N-dimethylformamide\water provided 1.8 g of the desired product as a white powder: MP: 183.0-184.0 °C; ¹H NMR (300 MHz, DMSO): δ 9.71 (s, 2H), 8.96 (s, 2H), 7.59-7.56 (d, J=9.0 Hz, 4H), 6.89-6.86 (d, J=9.0 Hz, 4H), 3.06 (s, 6H); ¹³C NMR (75 MHz, DMSO): δ 157.8, 151.7, 134.6, 120.7, 118.0, 38.0; IR (KBr): 3365, 3145, 2895, 1639, 1554, 1505, 1412, 1344, 1304, 1262, 1221, 1196, 1012, 876, 847, 814 cm⁻¹; Anal. calc'd for C₁₆H₁₈N₄O₄: C, 55.49; H, 5.24; N, 16.18. Found: C, 55.54; H, 5.30; N, 16.11.

Example 7

1,1'-(m-Phenylene)bis(3-hydroxy-3-methylurea)




5

The same general procedure as reported in Example 1 was followed. 1,3-Phenylene diisocyanate (2.0 g, 12.5 mmol), N-methylhydroxylamine-hydrochloride (3.1 g, 37 mmol), NaOH (1.6 g dissolved in 10 ml of water), diethyl ether (120 ml), and water (5 ml) were combined. Filtration of the reaction mixture provided 3.1 g of the desired product as a light tan powder: MP: 146.0-147.0 °C; ¹H NMR (300 MHz, DMSO): δ 9.80 (broad s, 2H), 8.77 (s, 2H), 7.80 (t, J=1.9 Hz, 1H), 7.20-7.06 (m, 3H), 3.05 (s, 6H); ¹³C NMR (75 MHz, DMSO): δ 157.8, 139.2, 128.0, 113.6, 110.8, 38.1; IR (KBr): 3400, 3182, 2898, 1660, 1616, 1544, 1498, 1344, 802, 737, 696, 607 cm⁻¹; MS (FAB): m/e 255.1076 (255.1093 calc'd for C₁₀H₁₅N₄O₄, M+H).

15

Example 8

1,1'-(1,5-Naphthalene)bis(3-hydroxy-3-methylurea)



20


The same general procedure as reported in Example 1 was followed. 1,5-Naphthalene diisocyanate (2.1 ml, 10 mmol), N-methylhydroxylamine-hydrochloride (2.5 g, 30 mmol), NaOH (1.3 g dissolved in 10 ml of water), diethyl ether (100 ml), and water (5 ml) were combined. The product formed as a precipitate. Recrystallization from N,N-dimethylformamide\water provided 1.4 g of the desired product as a white crystalline solid: MP: 190.0-191.0 °C (decomp); ¹H NMR (300 MHz, DMSO): δ 9.92 (s, 2H), 9.00 (s, 2H), 7.73 (d, J=8.4 Hz, 2H), 7.61 (d, J=7.0 Hz, 2H), 7.51-7.46 (m, 2H), 3.12 (s, 6H);

¹³C NMR (75 MHz, DMSO): δ 158.4, 134.0, 128.4, 125.0, 120.5, 118.4, 38.1; IR (KBr): 3413, 3170, 2874, 1646, 1537, 1506, 1451, 1402, 1347, 1261, 1173, 1122, 897, 778, 754, 715 cm^{-1} ; MS (FAB): m/e 305.1250 (305.1250 calc'd for C₁₄H₁₇N₄O₄, M+H); Anal. calc'd for C₁₄H₁₆N₄O₄: C, 55.26; H, 5.30; N, 18.41. Found: C, 55.04; H, 5.26; N, 18.37.

5

Example 9

trans-1,4-Cyclohexanebis(3-hydroxy-3-methylurea)




10

The same general procedure as reported in Example 1 was followed. 1,4-Cyclohexane diisocyanate (2.5 g, 15 mmol), N-methylhydroxylamine-hydrochloride (3.8 g, 45 mmol), NaOH (2.0 g dissolved in 10 ml of water), diethyl ether (120 ml), and water (5 ml) were combined. Filtration of the reaction mixture provided 3.8 g of the desired product as an off-white powder: MP: 186 $^{\circ}\text{C}$ (decomp); ¹H NMR (300 MHz, DMSO): δ 9.36 (broad s, 2H), 6.56-6.53 (d, $J=8.5$ Hz, 2H), 3.35 (broad s, 2H), 2.92 (s, 6H), 1.76-1.64 (m, 4H), 1.36-1.29 (m, 4H); ¹³C NMR (75 MHz, DMSO): δ 160.2, 47.9, 38.7, 31.7; MS (FAB): m/e 261.1557 (261.1563 calc'd for C₁₀H₂₁N₄O₄, M+H).

Example 10

1,1'-Hexamethylenebis(3-hydroxy-3-benzylurea)




5

The same general procedure as reported in Example 1 was followed. 1,6-Diisocyanatohexane (1.3 ml, 8.1 mmol), N-benzylhydroxylamine-hydrochloride (3.2 g, 20 mmol), NaOH (1.0 g dissolved in 10 ml of water), diethyl ether (100 ml), and water (5 ml) were combined. Filtration of the reaction mixture yielded 3.2 g of the desired product as a white powder. Recrystallization from N,N-dimethylformamide\water provided an analytically pure sample: MP: 181.0-182.0 °C; 1H NMR (300 MHz, DMSO): δ 9.26 (s, 2H), 7.34-7.20 (m, 10H), 6.94-6.89 (t, J=5.9 Hz, 2H), 4.50 (s, 4H), 3.08-3.01 (q, J=6.6 Hz, 4H), 1.43-1.20 (m, 8H); 13C NMR (75 MHz, DMSO): δ 160.4, 138.0, 128.0, 127.8, 126.6, 54.0, 39.4, 29.9, 26.1; IR (KBr): 3381, 3140, 2887, 1595, 1540, 1246, 1223, 1116, 744, 723, 694 cm⁻¹; MS (FAB): m/e 415.2361 (415.2345 calc'd for C₂₂H₃₁N₄O₄, M+H); Anal. calc'd for C₂₂H₃₀N₄O₄: C, 63.75; H, 7.30; N, 13.52. Found: C, 63.55; H, 7.49; N, 13.59.

Example 11

1,1'-(4,4'-(2,2'-Dimethoxy)biphenyl)bis(3-hydroxy-3-methylurea)




5

A solution of N-methylhydroxylamine-hydrochloride (1.1 g, 13.2 mmol), water (5 ml), and tetrahydrofuran (60 ml) was cooled to 0 °C and NaOH (0.65 g in 7 ml water) was added dropwise over a 10 min period. The reaction was maintained at 0 °C for 10 min followed by the addition of dianisidine diisocyanate (1.5 g, 5.1 mmol). A precipitate 10 formed within 5 min. The cooling bath was removed and the reaction was maintained at ambient temperature overnight. Filtration yielded 1.9 g of the desired product as a tan powder. Recrystallization from N,N-dimethylformamide\water provided an analytically pure sample: MP: 205 °C (decomp); 1H NMR (300 MHz, DMSO): δ 10.10 (s, 2H), 8.43 (s, 2H), 8.14 (d, J=8.4 Hz, 2H), 7.29 (d, J=1.9 Hz, 2H), 7.25-7.22 (dd, J=8.4, 1.9 Hz, 2H), 15 3.96 (s, 6H), 3.10 (s, 6H); 13C NMR (75 MHz, DMSO): δ 157.1, 147.6, 134.2, 126.7, 118.5, 117.5, 108.7, 56.0, 37.9; IR (KBr): 3399, 3151, 2884, 1635, 1610, 1589, 1539, 1254, 1122, 1027, 839, 758 cm⁻¹; MS (FAB): m/e 391.1625 (391.1618 calc'd for C₁₈H₂₃N₄O₆, M+H); Anal. calc'd for C₁₈H₂₂N₄O₆: C, 55.38; H, 5.68; N, 14.35. Found: C, 55.24; H, 5.27; N, 14.34.

20

Example 12

4,4'-Methylenebis(1-hydroxy-1-(1-ethylpropyl)-3-phenylurea)




25

A solution of 4,4'-methylenebis(phenylisocyanate) (1.5 g, 6.0 mmol) and tetrahydrofuran (75 ml) was charged with N-(1-ethylpropyl)hydroxylamine (1.5 g, 14.5 mmol) and maintained at ambient temperature for 16 hr. The solvent was removed *in vacuo* to provide the crude product as a white solid. Recrystallization from ethyl acetate\hexanes provided 1.0 g of the desired product as a white powder: MP: 196.0-198.0 °C (decomp); 1H NMR (300 MHz, DMSO): δ 9.16 (s, 2H), 8.78 (s, 2H), 7.50 (d, J=8.5 Hz, 4H), 7.05 (d, J= 8.5 Hz, 4H), 3.96-3.87 (m, 2H), 3.77 (s, 2H), 1.59-1.31 (m, 8H), 0.85-0.80 (t, J=7.3 Hz, 12H); 13C NMR (75 MHz, DMSO): δ 157.7, 137.4, 134.9, 128.2, 119.1, 59.6, 24.5, 11.0; IR (KBr): 3395, 3147, 2966, 2931, 2875, 1641, 1590, 1528, 1461, 1413, 1328, 1312, 1225, 1150, 815, 761 cm⁻¹; MS (FAB): m/e 457.2804 (457.2815 calc'd for C₂₅H₃₇N₄O₄, M+H); Anal. calc'd for C₂₅H₃₆N₄O₄: C, 65.76; H, 7.95; N, 12.27. Found: C, 65.53; H, 7.87; N, 12.11.

Example 13

15 1,1'-(m-Phenylene)bis(1-methyl-1-(3-hydroxy-3-(1-ethylpropyl)ureido)ethane)




A solution of 1,3-Bis(1-isocyanato-1-methylethyl)benzene (2.3 ml, 10 mmol) and dichloromethane (100 ml) was charged with N-(1-ethylpropyl)hydroxylamine (2.2 g, 21.3 mmol). A precipitate formed immediately and the resulting mixture was maintained overnight. The precipitate was recovered by filtration and dried *in vacuo* to yield 4.0 g of the desired product as a white powder. Recrystallization from N,N-dimethylformamide\water provided an analytically pure sample: MP: 170.5-172.0 °C ;

5 $^1\text{H NMR}$ (300 MHz, DMSO): δ 8.91 (s, 2H), 7.37 (s, 1H), 7.18 (apparent d, $J=1.0$ Hz, 3H), 6.53 (s, 2H), 3.75-3.65 (m, 2H), 1.57 (s, 12H), 1.51-1.30 (m, 8H), 0.80 (t, $J=7.3$ Hz, 12 H); $^{13}\text{C NMR}$ (75 MHz, DMSO): δ 159.3, 147.7, 127.1, 122.2, 121.0, 59.5, 54.3, 29.8, 24.4, 11.2; IR (KBr): 3436, 3160, 2963, 2928, 2873, 1632, 1520, 1380, 1361, 1270, 1232, 1160, 790, 702 cm^{-1} ; Anal. calc'd for $\text{C}_{24}\text{H}_{42}\text{N}_4\text{O}_4$: C, 63.97; H, 9.39; N, 12.43. Found: C, 63.81; H, 9.35; N, 12.48.

10 Example 14


4,4'-Oxybis(1-hydroxy-1-(1-ethylpropyl)-3-phenylurea)



15 The same general procedure as reported in Example 13 was followed. 4,4'-Oxybis(phenylisocyanate) (2.52 g, 10 mmol), N-(1-ethylpropyl)hydroxylamine (2.2 g, 21 mmol), and dichloromethane (100 ml) were combined. The product formed as a precipitate. Purification by recrystallization from N,N-dimethylformamide\water yielded 3.5 g of the desired product as a white powder: MP: 182.0 $^{\circ}\text{C}$ (decomp); $^1\text{H NMR}$ (300 MHz, DMSO): δ 9.16 (s, 2H), 8.89 (s, 2H), 7.58 (d, $J=9.0$ Hz, 4H), 6.86 (d, $J=9.0$ Hz, 4H), 3.98-3.88 (septet, $J=4.7$ Hz, 2H), 1.60-1.33 (m, 8H), 0.84 (t, $J=7.3$ Hz, 12 H); $^{13}\text{C NMR}$ (75 MHz, DMSO): δ 157.7, 151.6, 134.9, 120.6, 118.0, 59.6, 24.5, 11.0; IR (KBr): 3405, 3138, 2967, 2929, 2875, 1638, 1591, 1533, 1503, 1461, 1412, 1243, 1221, 1161, 1106, 831, 813, 735 cm^{-1} ; MS (FAB): m/e 459.2619 (459.2607 calc'd for $\text{C}_{24}\text{H}_{35}\text{N}_4\text{O}_5$, M+H); Anal. calc'd for $\text{C}_{24}\text{H}_{34}\text{N}_4\text{O}_5$: C, 62.86; H, 7.47; N, 12.22. Found: C, 62.56; H, 7.53; N, 12.18.

Example 15

1,1'-(p-Phenylene)bis(3-hydroxy-3-(1-ethylpropyl)urea)




5

The same general procedure as reported in Example 13 was followed. 1,4-Phenylene diisocyanate (3.2 g, 20 mmol), N-(1-ethylpropyl)hydroxylamine (4.3 g, 42 mmol), and dichloromethane (200 ml) were combined. The product formed as a precipitate. Purification by recrystallization from N,N-dimethylformamide\water yielded 10 4.6 g of the desired product as a white powder: MP: 202.0 °C (decomp); ¹H NMR (300 MHz, DMSO): δ 9.13 (s, 2H), 8.72 (s, 2H), 7.44 (s, 4H), 3.96-3.87 (septet, J=4.7 Hz, 2H), 1.60-1.33 (m, 8H), 0.84 (t, J=7.3 Hz, 12 H); ¹³C NMR (75 MHz, DMSO): δ 157.9, 134.0, 119.3, 59.6, 24.6, 11.1; IR (KBr): 3401, 3134, 2964, 2923, 2873, 1634, 1541, 1462, 1412, 1269, 1218, 1159, 1103, 1060, 833, 755, 736 cm⁻¹; MS (FAB): m/e 367.2331 (367.2345 15 calc'd for C₁₈H₃₁N₄O₄, M+H); Anal. calc'd for C₁₈H₃₀N₄O₄: C, 59.00; H, 8.25; N, 15.29. Found: C, 58.72; H, 8.34; N, 15.28.

Example 16

1,1'-(4-Methyl-m-phenylene)bis(3-hydroxy-3-(1-ethylpropyl)urea)




5

Tolylene 2,4-diisocyanate (2.9 ml, 20 mmol) was added dropwise to a solution of N-(1-ethylpropyl)hydroxylamine (4.4 g, 43 mmol) in dichloromethane (200 ml). After a few minutes, a precipitate formed. The resulting mixture was maintained overnight. Filtration followed by drying of the precipitate (*in vacuo*) yielded 7.5 g of the desired product as a white powder. Recrystallization from N,N-dimethylformamide\water provided an analytically pure sample: MP: 175.0-177.0 °C ; 1H NMR (300 MHz, DMSO): δ 9.26 (s, 1H), 9.13 (s, 1H), 8.70 (s, 1H), 8.16 (s, 1H), 7.85 (d, J=2.2 Hz, 1H), 7.24 (dd, J= 8.2, 2.2 Hz, 1H), 7.01 (d, J=8.5 Hz, 1H), 3.96-3.86 (m, 2H), 2.12 (s, 3H), 1.62-1.33 (m, 8H), 0.85 (t, J=7.3 Hz, 6H), 0.83 (t, J=7.3 Hz, 6H); IR (KBr): 3395, 3145, 2967, 2930, 2875, 1640, 1529, 1488, 1458, 1422, 1242, 1150, 1123, 1105 cm⁻¹; MS (FAB): m/e 381.2518 (381.2502 calc'd for C₁₉H₃₃N₄O₄, M+H); Anal. calc'd for C₁₉H₃₂N₄O₄: C, 59.98; H, 8.48; N, 14.72. Found: C, 59.41; H, 8.40; N, 14.75.

Example 17

20 1,1'-(2-Methylpentamethylene)bis(3-hydroxy-3-(1-ethylpropyl)urea)



1,5-Diisocyanato-2-methylpentane (3.2 ml, 20 mmol) was added dropwise to a solution of N-(1-ethylpropyl)hydroxylamine (4.4 g, 43 mmol) in dichloromethane (200


ml). The reaction was maintained overnight and then concentrated (*in vacuo*) to a volume of approximately 20 ml. Purification of the sample by flash column chromatography (96:4 dichloromethane\methanol, R_f 0.26) followed by recrystallization from N,N-dimethylformamide\water provided 2.6 g of the desired product as a white powder: MP:

5 124.0-125.0 $^{\circ}\text{C}$; $^1\text{H NMR}$ (300 MHz, DMSO): δ 8.70 (s, 1H), 8.66 (s, 1H), 6.73 (t, J =6.0 Hz, 1H), 6.68 (t, J =7.0 Hz, 1H), 3.81-3.72 (m, 2H), 3.02-2.78 (m, 4H), 1.60-0.98 (m, 13H), 0.83-0.77 (m, 15H); $^{13}\text{C NMR}$ (75 MHz, DMSO): δ 160.95, 160.92, 59.9, 45.4, 39.6, 33.1, 31.2, 27.5, 24.5, 17.5, 11.1; IR (KBr): 3428, 3177, 2969, 2930, 2876, 1639, 1540, 1462, 1378, 1266, 1167, 1142, 1062, 1034, 929, 770 cm^{-1} ; MS (FAB): m/e 10 375.2957 (375.2971 calc'd for $\text{C}_{18}\text{H}_{39}\text{N}_4\text{O}_4$, $\text{M}+\text{H}$); Anal. calc'd for $\text{C}_{18}\text{H}_{38}\text{N}_4\text{O}_4$: C, 57.73; H, 10.23; N, 14.96. Found: C, 57.90; H, 10.19; N, 14.93.

Example 18

1,1'-Octamethylenebis(3-hydroxy-3-(1-ethylpropyl)urea)

15




The same general procedure as reported in Example 16 was followed. 1,8-Diisocyanatoctane (3.9 ml, 20 mmol), N-(1-ethylpropyl)hydroxylamine (4.3 g, 42 mmol), 20 and dichloromethane (200 ml) were combined to provide 7.4 g of the desired product as a white powder: MP: 89.0-90.0 $^{\circ}\text{C}$; $^1\text{H NMR}$ (500 MHz, DMSO): δ 8.65 (s, 2H), 6.71 (t, J =5.9 Hz, 2H), 3.78 (m, 2H), 3.01 (q, J =6.7 Hz, 4H), 1.49-1.21 (m, 20H), 0.79 (t, J =7.5 Hz, 12H); $^{13}\text{C NMR}$ (125 MHz, DMSO): δ 161.2, 60.1, 39.3, 29.9, 28.9, 26.3, 24.5, 11.1; IR (KBr): 3444, 3128, 2962, 2933, 2856, 1628, 1537, 1473, 1358, 1319, 1271, 1165, 1140, 25 1105, 1070, 1039, 927, 839, 779, 748 cm^{-1} ; MS (FAB): m/e 403.3277 (403.3284 calc'd for $\text{C}_{20}\text{H}_{43}\text{N}_4\text{O}_4$, $\text{M}+\text{H}$), 300; Anal. calc'd for $\text{C}_{20}\text{H}_{42}\text{N}_4\text{O}_4$: C, 59.67; H, 10.51; N, 13.92. Found: C, 59.71; H, 10.65; N, 13.92.

Example 19

4,4'-Methylenebis(1-hydroxy-1-(1-ethylpropyl)-3-(2-chlorophenyl)urea)

5



The same general procedure as reported in Example 16 was followed. 5-Methylenebis(o-chlorophenyl isocyanate) (3.19 g, 10 mmol), N-(1-ethylpropyl)hydroxylamine (2.15 g, 21 mmol), and dichloromethane (100 ml) were combined to provide 4.6 g of the desired product as a white powder: MP: 172.0-173.0 °C ; 1H NMR (500 MHz, DMSO): δ 9.62 (s, 2H), 8.50 (s, 2H), 8.04 (d, J=8.5 Hz, 2H), 7.36 (d, J=1.8 Hz, 2H), 7.18 (dd, J=8.5, 1.8 Hz, 2H), 3.94 (septet, J=4.8 Hz, 2H), 3.85 (s, 2H), 1.56-1.39 (m, 8H), 0.83 (t, J=7.4 Hz, 12H); 13C NMR (125 MHz, DMSO): δ 157.0, 136.7, 133.6, 128.9, 128.0, 122.3, 120.8, 59.9, 38.8, 24.6, 11.0; IR (KBr): 3375, 3143, 2962, 2931, 2875, 1645, 1602, 1575, 1525, 1403, 1305, 1269, 1232, 1157, 1101, 1045, 821, 765, 736 cm⁻¹; MS (FAB): m/e 525.2041 (525.2035 calc'd for C₂₅H₃₅N₄O₄Cl₂, M+H).

5-LIPOXYGENASE INHIBITION IN HUMAN LEUKOCYTES

The test method described below measures the ability of compounds of the invention to inhibit 5-lipoxygenase activity in human leukocytes.

Blood Cell Preparation

Whole human blood is collected by venipuncture into EDTA (1.4 mL of 0.25M per 60 mL of whole blood). The red blood cells are sedimented with a 6% dextran/0.9% sodium chloride solution at a ratio of 25 mL whole blood to 15 mL dextran solution. The blood/dextran combination is mixed by inversion and the red blood cells are allowed to settle out for 45 minutes at ambient temperature. The plasma/dextran supernatant is

removed then centrifuged at ambient temperature at 3000 rpm for 10 minutes. The plasma/dextran supernatant is removed and the cells are resuspended in 10 mL of the plasma/dextran solution. The cell suspension is combined with 20 mL of water, mixed for 1.5 minutes then immediately combined with 10 mL of 3.6% sodium chloride, mixed and 5 centrifuged at ambient temperature at 3000 rpm for 10 minutes. The pellet is washed with 40 mL of Tris buffer (5.55 mM dextrose, 15.36 mM Tris base, 136.9 mM sodium chloride with pH 7.3-7.4) then centrifuged at 3000 rpm for 10 minutes. The pellet is then resuspended into Tris buffer containing 1 mM calcium chloride to provide approximately 1.0 X 10⁷ cells/mL.

10

Compound Preparation

Compounds are dissolved in dimethyl sulfoxide. Compounds are tested at concentrations of 100, 33, 11, 3.7, 1.2 and 0.41 μ M. Each concentration is tested in duplicate.

15

Incubation

A 15 μ L portion of Tris buffer containing 1 mM calcium chloride is added to each well of a 96 well microtiter plate. A 1 μ L portion of drug solution or vehicle (dimethyl sulfoxide) is added to each well followed by the addition of a 75 μ L portion of the cell 20 suspension. The plates are gently mixed then allowed to stand at ambient temperature for 10 minutes. A 10 μ L portion of 30 μ M A23187 Calcium Ionophore (prepared by dissolving the ionophore in DMSO and then diluting 1:80 into the Tris buffer) is added to each well except the wells that contain the blanks. The blank wells measure the level of LTC₄ production in the absence of A23187. The plates are gently mixed then incubated at 25 37°C for 10 minutes.

Separation

Following incubation the plates are centrifuged at 2000 rpm for 1.5 minutes and the supernatant is removed as quickly as possible to stop the reaction. The supernatants 30 are frozen at -20°C until they are assayed.

Analysis/Calculations

The supernatants are assayed for the presence of Leukotriene C₄ by radioimmunoassay which is performed according to the manufacturer's instructions (Advanced Magnetics; Cambridge, MA). Inhibition of leukotriene biosynthesis is 5 calculated as the ratio of the amount of LTC₄ formed in the presence (LTC₄ + cpd) and absence (LTC₄ no cpd) of compound according to the following equation.

$$\% \text{ Inhibition} = \frac{(\text{LTC}_4 \text{ no cpd}) - (\text{LTC}_4 + \text{cpd})}{(\text{LTC}_4 \text{ no cpd})} \times 100$$

10

IC₅₀ values (concentrations of compound producing 50% leukotriene biosynthesis inhibition) are calculated by linear regression analysis of percentage inhibition versus log compound concentration plots.

15 A number of compounds of the invention were tested according to the above method and the results are shown in Table 1 below.

Table 1	
5-Lipoxygenase Inhibition in Human Leukocytes	
Compound of Example	IC ₅₀ (μM)
4	4.22
5	0.024
6	0.216
7	5.9
8	5.6
9	>10.0
10	0.1
11	0.1
12	0.020
13	65.0
14	0.1

Table 1	
5-Lipoxygenase Inhibition in Human Leukocytes	
Compound of Example	IC ₅₀ (μM)
15	2.1
16	58.6
17	12.0
18	0.33
19	0.11

IN VITRO HUMAN WHOLE BLOOD LEUKOTRIENE B₄ INHIBITION

The test method described below measures the ability of compounds to inhibit the 5 production of Leukotriene B₄ in whole human blood.

Blood Cell Preparation

Whole human blood is collected by venipuncture into a 60 cc syringe containing 100 units of heparin.

10

Compound Preparation

Compounds are dissolved in dimethyl sulfoxide. Compounds are tested at concentrations of 100, 33, 11, 3.7, 1.2 and 0.41 μM. Each concentration is tested in duplicate.

15

Incubation

Aliquots (1 μL) of compound solution are added to 1 mL polyethylene tubes followed by the addition of a 500 μL portion of heparinized blood. The tubes are mixed thoroughly then allowed to preincubate at ambient temperature for 15 minutes. A 25 μL 20 portion of 1mM Calcium Ionophore A23187 in dimethyl sulfoxide/Tris buffer is added to the tubes. The tubes are mixed thoroughly then incubated at 37°C for 30 minutes.

Separation

The tubes are centrifuged at 2000 rpm for 10 minutes. 100 μ L portions of plasma are transferred to 1 mL polyethylene tubes containing 400 μ L portions of methanol. The tubes are vortexed then frozen at -20°C overnight.

5

Analysis/Calculations

The tubes are centrifuged for 10 minutes then 100 μ L portions of methanol supernatant are transferred to a 96 well microtiter plate. 10 μ L portions are transferred from this plate to a 96 well assay plate. Methanol dilutions of LTB₄ standard curve are 10 added to the assay plate. 10 μ L portions of blank methanol/plasma supernatant are added to each standard curve well. The assay plate is vacuum dried at ambient temperature. The radioimmunoassay buffer is added, the plate is bath-sonicated for 5 minutes then assayed according to the manufacturer's instructions (Advanced Magnetics; Cambridge, MA). Inhibition of LTB₄ production is calculated as the ratio of the amount of LTB₄ formed in 15 the presence (LTB₄ + cpd) and absence (LTB₄ no cpd) of compound according the equation below.

$$\% \text{ Inhibition} = \frac{(\text{LTB}_4 \text{ no cpd}) - (\text{LTB}_4 + \text{cpd})}{(\text{LTB}_4 \text{ no cpd})} \times 100$$

20

IC₅₀ values (concentration of compound producing a 50% inhibition of LTB₄ production) are calculated by linear regression analysis of percentage inhibition versus log compound concentration plots.

25 A number of compounds of the invention were tested according to the above method. The results are shown in Table 2 below.

Table 2

In Vitro Human Whole Blood Leukotriene B ₄ Inhibition	
Compound of Example	IC ₅₀ (μM)
1	0.55
2	1.7
3	0.32
4	8.2
5	0.7
6	0.5
7	0.55
8	0.7
9	17.2
10	2.0
11	0.35

**IN VITRO MOUSE PERITONEAL MACROPHAGE
LEUKOTRIENE C₄ INHIBITION**

5 The test method described below measures the ability of compounds to inhibit the production of Leukotriene C₄ in mouse peritoneal macrophages.

Cell Preparation

Mice (female, CD-1, weighing 25 g) are euthanized by exposure to carbon dioxide.

10 The peritoneal cavity is exposed by peeling back the abdominal skin. A 5 mL portion of media (M199 containing 1% fetal bovine serum, 100 units/mL of penicillin, 100 μg/mL of streptomycin, 20 units/mL of heparin and no glutamine) is injected into the exposed peritoneal cavity of each mouse. The lavage fluid is removed and pooled to yield approximately 1 X 10⁶ macrophages/mL. A 2 mL portion of lavage fluid is added to each 15 well of a 24 well sterile multidish and the macrophages are allowed to adhere to the plate for 2 hours at 37°C in a 5% carbon dioxide atmosphere. The media is removed and each

well is washed with 2 mL of phosphate buffered saline (PBS). A 1 mL portion of media, without heparin, but containing 5 μ Ci/mL of 3H-myoinositol is added to each well and the plates are incubated overnight at 37°C in a 5% carbon dioxide atmosphere. The media is removed and the cells are washed twice with 2 mL portions of PBS. A 1 mL portion of

5 Puck's saline formulation A containing 1 mM calcium chloride, 1 mM magnesium chloride and 10 mM lithium chloride is added to each well. (The Puck's formulation is made first as a 10X solution which contains 4 g of potassium chloride, 80 g of sodium chloride and 10 g of glucose per liter. The Puck's saline formulation A is made using 10 mL of the 10X Puck's formulation, 0.47 mL of 7.5% sodium bicarbonate and 2 mL of 1M

10 N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid per 100 mL.)

Compound Preparation

Compounds are dissolved in dimethyl sulfoxide. Compounds are tested at concentrations of 10, 1 and 0.1 μ M. Each concentration is tested in duplicate.

15

Incubation

A 1 μ L portion of compound solution or vehicle (DMSO) is added to each well and the plates are incubated for 15 minutes at 37°C in a 5% carbon dioxide atmosphere. Zymosan is then added to provide a final concentration of 50 μ g/mL in each well and the

20 plate is incubated for 1 to 2 hours at 37°C in a 5% carbon dioxide atmosphere.

Separation

Following incubation 200 μ L portions of media are transferred to 12 X 75 mm tubes. The tubes are either assayed immediately or stored at -20°C until they can be

25 assayed.

Analysis/Calculations

The media is assayed for the presence of Leukotriene C₄ by radioimmunoassay which is performed according to the manufacturer's instructions (Advanced Magnetics; 30 Cambridge, MA). Inhibition of LTC₄ production is calculated as the ratio of the amount of

LTC₄ formed in the presence (LTC₄+ cpd) and absence (LTC₄ no cpd) of compound according to the equation below.

$$5 \quad \text{% Inhibition} = \frac{(\text{LTC}_4 \text{ no cpd}) - (\text{LTC}_4 + \text{cpd})}{(\text{LTC}_4 \text{ no cpd})} \times 100$$

IC₅₀ values (concentration of compound producing a 50% inhibition of LTC₄ production) are calculated by linear regression analysis of percentage inhibition versus log compound concentration plots.

10

A number of compounds of the invention were tested according to the above method. The results are shown in Table 3 below.

Table 3

In Vitro Mouse Peritoneal Macrophage Leukotriene C ₄ Inhibition			
Compound of Example	Percent Inhibition		
	10.0 μM	1.0 μM	0.1 μM
1	100	95	61
2	54	55	32
3	74	56	25
4	67	6	-24
5	100	100	91
6	99	99	48
7	98	7	-19
8	91	76	55
9	-6	1	1
10	94	94	7
11	99	100	42
12	100	93	83

RAT EX VIVO LEUKOTRIENE B₄ INHIBITION

The test method described below measures the ability of a compound when administered orally to rats to inhibit the production of Leukotriene B₄ in their blood which
5 is drawn and challenged.

Rats (CD, male, non-fasted, 250 g) are lightly anesthetized with carbon dioxide and an approximately 0.75 mL sample of whole blood is obtained via cardiac puncture. The sample is dispensed into 12 X 75 mm polypropylene tubes containing 8-10 μ L of 10,000 units/mL heparin, mixed and then maintained on ice. The rats are allowed to recover
10 approximately one hour then dosed orally with compound dissolved in PEG 400 at a 5 mL/Kg volume. Five (5) rats are utilized per group. Two (2) hours post dose the rats are again anesthetized with carbon dioxide and the blood sampled again via cardiac puncture.

Duplicate 200 μ L portions of blood are added to 1.0 mL polypropylene tubes. A 10 μ L portion of 1mM A23187 Calcium Ionophore in dimethyl sulfoxide/Tris buffer is
15 added to each tube. The tubes are gently vortexed then incubated in a 37°C water bath for 30 minutes. The tubes are then centrifuged at 4000 rpm for 10 minutes. 50 μ L portions of plasma are transferred to 1.0 mL tubes containing 200 μ L of methanol. The tubes are vortexed then placed in the freezer overnight.

The tubes are removed from the freezer then centrifuged at 4000 rpm for 10
20 minutes. 20 μ L portions of the methanol/plasma supernatant and 10 μ L methanol dilutions of LTB₄ standard are transferred to 96 well v-bottom microtiter plates. The plates are vacuum dried at 40°C. A 40 μ L portion of LTB₄ radioimmunoassay buffer is added to each well. The plate is bath sonicated for 5 minutes then assayed according to the manufacturer's instructions (Advanced Magnetics; Cambridge, MA). Percent
25 inhibition values are obtained by comparing the level of LTB₄ in the post-dose samples to the level in the pre-dose samples according to the equation below.

$$\% \text{ Inhibition} = \frac{(\text{LTB}_4 \text{ pre-dose}) - (\text{LTB}_4 \text{ post-dose})}{(\text{LTB}_4 \text{ pre-dose})} \times 100$$

A number of compounds of the invention were tested. The results are shown in Table 4 below.

Table 4		
Rat Ex Vivo Leukotriene B ₄ Inhibition		
Compound of Example	Dose (mg/Kg)	% Inhibition
1	10	16
1	50	93
2	50	34
3	50	6
7	50	59
9	50	4
10	50	8
11	50	4
12	50	15


5

The foregoing specification and examples provide a complete description of the invention, which resides in the following claims.

The claimed invention is:

1. A compound of the formula (I)

5



or a pharmaceutically acceptable salt thereof, wherein

10 M is selected from the group consisting of hydrogen, a pharmaceutically acceptable cation, and a pharmaceutically acceptable metabolically cleavable group;

R₁ and R₂ are independently selected from the group consisting of hydrogen and C₁₋₆ straight or branched chain alkyl;

R₃ and R₄ are independently selected from the group consisting of C₁₋₁₄ straight or branched chain alkyl optionally substituted by a group selected from halogen, nitro, hydroxyl, carboxyl and amino, and optionally interrupted by -O-, -S(O)₀₋₂-, -NR- wherein R is as defined below, or -CO-; and arylalkyl wherein the alkyl group is straight or branched chain and has from one to eight carbon atoms and the aryl group is phenyl optionally substituted with one or more substituents selected from the group consisting of C₁₋₆ straight or branched chain alkyl and halogen;

15 A is selected from the group consisting of:


(a) phenylene optionally substituted with one or more substituents selected from the group consisting of C₁₋₆ straight or branched chain alkyl and halogen;

(b) C₃₋₈ cycloalkylene;

20 (c) C₁₋₁₂ straight or branched chain alkylene;


(d) naphthalene optionally substituted with one or more substituents selected from the group consisting of C₁₋₆ straight or branched chain alkyl and halogen;

(e)



wherein each R₅ and R₆ is independently selected from the group consisting of
 5 hydrogen and C₁₋₃ straight or branched chain alkyl; and

(f)



wherein

10 each R₇ and R₈ is independently selected from the group consisting of hydrogen, C₁₋₃ straight or branched chain alkyl, C₁₋₃ straight or branched chain alkoxy, and halogen;

m is 1 or 2;

n is 1 or 2; and

B is selected from the group consisting of

15 (i) a carbon-carbon bond,


(ii) oxy,

(iii) thio,

(iv) sulfone,

(v) carbonyl,


20 (vi)



wherein R is selected from the group consisting of hydrogen and C₁₋₃ straight or branched chain alkyl,

(vii) —(CH₂)_p— wherein p is an integer from 1 to 14, and

(viii)



wherein R₉ and R₁₀ are independently selected from the group consisting of hydrogen, C₁₋₃ straight or branched chain alkyl, C₃₋₆ cycloalkyl, and trifluoromethyl;

5 with the proviso that R₃ and R₄ are other than *tertiary*-butyl and with the further proviso that when A is 2,4-toluene then R₃ and R₄ are other than methyl or ethyl and R₁ and R₂ are other than hydrogen.

10 2. A compound according to Claim 1, wherein R₁ and R₂ are both hydrogen.

3. A compound according to Claim 1, wherein R₃ and R₄ are the same.

15 4. A compound according to Claim 3, wherein R₃ and R₄ are selected from the group consisting of C₁₋₁₄ straight or branched chain alkyl and phenylalkyl wherein the alkyl group is straight or branched chain and has from one to eight carbon atoms.


5. A compound according to Claim 4, wherein R₃ and R₄ are selected from the group consisting of methyl, isopropyl, 1-ethylpropyl and benzyl.

20

6. A compound according to Claim 1, wherein A is selected from the group consisting of

- (a) C₁₋₁₂ straight or branched chain alkylene and
- (b)

25



wherein each R_7 and R_8 is independently selected from the group consisting of hydrogen, C_{1-3} straight or branched chain alkyl, C_{1-3} straight or branched chain alkoxy, and halogen;

5 m is 1 or 2;

n is 1 or 2; and

 B is selected from the group consisting of

(i) a carbon-carbon bond,


(ii) oxy,

10 (iii) thio,

(iv) sulfone,

(v) carbonyl,


(vi)



15 wherein R is selected from the group consisting of hydrogen and C_{1-3} straight or branched chain alkyl,

(vii) $—(\text{CH}_2)_p—$ wherein p is an integer from 1 to 14, and

(viii)




20 wherein R_9 and R_{10} are independently selected from the group consisting of hydrogen, C_{1-3} straight or branched chain alkyl, C_{3-6} cycloalkyl, and trifluoromethyl.

7. A compound according to Claim 6, wherein R_7 and R_8 are the same and are selected from the group consisting of hydrogen, C_{1-3} alkoxy and halogen, and m and n are both 1.

8. A compound according to Claim 7, wherein R₇ and R₈ are hydrogen or chloro.

9. A compound according to Claim 6, wherein B is selected from the group
5 consisting of

- (a) a carbon-carbon bond;
- (b) oxy; and
- (c)



10


wherein R₉ and R₁₀ are independently selected from the group consisting of hydrogen, C₁₋₃ straight or branched chain alkyl and trifluoromethyl.

10. A compound according to Claim 9, wherein R_9 and R_{10} are the same and are
15 selected from the group consisting of hydrogen and trifluoromethyl.

11. A compound according to Claim 1, wherein M is hydrogen.

12. A compound of the formula

20




or a pharmaceutically acceptable salt thereof, wherein

R' is selected from the group consisting of C₁₋₁₄ straight or branched chain alkyl and benzyl;

R" is selected from the group consisting of hydrogen, C₁₋₃ straight or branched chain alkyl, halogen, and C₁₋₃ straight or branched chain alkoxy; and

B is selected from the group consisting of

- 5 (a) a carbon-carbon bond;
- (b) oxy; and
- (c) the formula



wherein R₉ and R₁₀ are the same and are selected from the group consisting of hydrogen and trifluoromethyl;

10 with the proviso that R' is other than *tertiary*-butyl.

13. A compound according to Claim 12, wherein B is methylene or oxy.

14. A compound according to Claim 1, wherein the compound is selected from

15 the group consisting of

4,4'-Methylenebis(1-hydroxy-1-isopropyl-3-phenylurea);

4,4'-Methylenebis(1-hydroxy-1-benzyl-3-phenylurea);

4,4'-Methylenebis(1-hydroxy-1-methyl-3-(2,6-diethylphenyl)urea);

4,4'-Oxybis(1-hydroxy-1-methyl-3-phenylurea);

20 1,1'-(m-Phenylene)bis(3-hydroxy-3-methylurea);

1,1'-(1,5-Naphthalene)bis(3-hydroxy-3-methylurea);

trans-1,4-Cyclohexanebis(3-hydroxy-3-methylurea);

1,1'-Hexamethylenebis(3-hydroxy-3-benzylurea);

1,1'-(4,4'-(2,2'-Dimethoxy)biphenyl)bis(3-hydroxy-3-methylurea);

25 1,1'-(m-Phenylene)bis(1-methyl-1-(3-hydroxy-3-(1-ethylpropyl)ureido)ethane);

1,1'-(p-Phenylene)bis(3-hydroxy-3-(1-ethylpropyl)urea);

1,1'-(4-Methyl-m-phenylene)bis(3-hydroxy-3-(1-ethylpropyl)urea);

1,1'-(2-Methylpentamethylene)bis(3-hydroxy-3-(1-ethylpropyl)urea); and

1,1'-Octamethylenebis(3-hydroxy-3-(1-ethylpropyl)urea).

15. A compound according to Claim 1, wherein the compound is selected from the group consisting of


5 4,4'-Methylenebis(1-hydroxy-1-methyl-3-phenylurea);
 4,4'-(2,2-Hexafluoropropane)bis(1-hydroxy-1-methyl-3-phenylurea);
 4,4'-Methylenebis(1-hydroxy-1-(1-ethylpropyl)-3-phenylurea);
 4,4'-Oxybis(1-hydroxy-1-(1-ethylpropyl)-3-phenylurea); and
 4,4'-Methylenebis(1-hydroxy-1-(1-ethylpropyl)-3-(2-chlorophenyl)urea).

10

16. A pharmaceutical composition comprising

(i) a pharmaceutically acceptable vehicle; and
 (ii) a therapeutically effective amount of a compound of the formula (I)

15



or a pharmaceutically acceptable salt thereof, wherein

M is selected from the group consisting of hydrogen, a pharmaceutically acceptable cation, and a pharmaceutically acceptable metabolically cleavable group;


R₁ and R₂ are independently selected from the group consisting of hydrogen and C₁₋₆ straight or branched chain alkyl;

R₃ and R₄ are independently selected from the group consisting of C₁₋₁₄ straight or branched chain alkyl optionally substituted by a group selected from halogen, nitro, hydroxyl, carboxyl and amino, and optionally interrupted by -O-, -S(O)₀₋₂-, -NR- wherein R is as defined below, or -CO-; and arylalkyl wherein the alkyl group is straight or branched chain and has from one to eight carbon atoms and the aryl group is phenyl

optionally substituted with one or more substituents selected from the group consisting of C₁₋₆ straight or branched chain alkyl and halogen;


A is selected from the group consisting of:

- (a) phenylene optionally substituted with one or more substituents selected from
- 5 the group consisting of C₁₋₆ straight or branched chain alkyl and halogen;
- (b) C₃₋₈ cycloalkylene;
- (c) C₁₋₁₂ straight or branched chain alkylene;
- (d) naphthalene optionally substituted with one or more substituents selected from the group consisting of C₁₋₆ straight or branched chain alkyl and halogen;
- 10 (e)



wherein each R₅ and R₆ is independently selected from the group consisting of hydrogen and C₁₋₃ straight or branched chain alkyl; and

- (f)



15

wherein

each R₇ and R₈ is independently selected from the group consisting of hydrogen, C₁₋₃ straight or branched chain alkyl, C₁₋₃ straight or branched chain alkoxy, and halogen;

20 m is 1 or 2;


n is 1 or 2; and

B is selected from the group consisting of

- (i) a carbon-carbon bond,
- (ii) oxy,
- 25 (iii) thio,
- (iv) sulfone,

(v) carbonyl,


(vi)



5 wherein R is selected from the group consisting of hydrogen and C₁₋₃ straight or branched chain alkyl,

(vii) —(CH₂)_p— wherein p is an integer from 1 to 14, and

(viii)




10

wherein R₉ and R₁₀ are independently selected from the group consisting of hydrogen, C₁₋₃ straight or branched chain alkyl, C₃₋₆ cycloalkyl; and trifluoromethyl.

15

17. A method of inhibiting the enzyme 5-lipoxygenase in an animal comprising administering to the animal, in an amount effective to inhibit the enzyme 5-lipoxygenase, a compound of the formula (I)



20

(I)


or a pharmaceutically acceptable salt thereof, wherein

M is selected from the group consisting of hydrogen, a pharmaceutically acceptable cation, and a pharmaceutically acceptable metabolically cleavable group;


R₁ and R₂ are independently selected from the group consisting of:
hydrogen and C₁₋₆ straight or branched chain alkyl;

R₃ and R₄ are independently selected from the group consisting of C₁₋₁₄ straight or branched chain alkyl optionally substituted by a group selected from halogen, nitro,
5 hydroxyl, carboxyl and amino, and optionally interrupted by -O-, -S(O)₀₋₂-, -NR- wherein R is as defined below, or -CO-; and arylalkyl wherein the alkyl group is straight or branched chain and has from one to eight carbon atoms and the aryl group is phenyl optionally substituted with one or more substituents selected from the group consisting of C₁₋₆ straight or branched chain alkyl and halogen;

10 A is selected from the group consisting of:
(a) phenylene optionally substituted with one or more substituents selected from the group consisting of C₁₋₆ straight or branched chain alkyl and halogen;
(b) C₃₋₈ cycloalkylene;
(c) C₁₋₁₂ straight or branched chain alkylene;
15 (d) naphthalene optionally substituted with one or more substituents selected from the group consisting of C₁₋₆ straight or branched chain alkyl and halogen;
(e)



20 wherein each R₅ and R₆ is independently selected from the group consisting of hydrogen and C₁₋₃ straight or branched chain alkyl; and
(f)



25 wherein

each R_7 and R_8 is independently selected from the group consisting of hydrogen, $C_{1,3}$ straight or branched chain alkyl, $C_{1,3}$ straight or branched chain alkoxy, and halogen;

m is 1 or 2;

n is 1 or 2; and

5 B is selected from the group consisting of

(i) a carbon-carbon bond,


(ii) oxy,

(iii) thio,

(iv) sulfone,

10 (v) carbonyl,


(vi)



wherein R is selected from the group consisting of hydrogen and $C_{1,3}$ straight or
15 branched chain alkyl,

(vii) $—(CH_2)_p—$ wherein p is an integer from 1 to 14, and


(viii)



20 wherein R_9 and R_{10} are independently selected from the group consisting of
hydrogen, $C_{1,3}$ straight or branched chain alkyl, $C_{3,6}$ cycloalkyl, and
trifluoromethyl.

18. A method of treating in an animal a condition responsive to the inhibition of the enzyme 5-lipoxygenase comprising administering to the animal, in an amount effective to inhibit the enzyme 5-lipoxygenase, a compound of the formula (I)

5



or a pharmaceutically acceptable salt thereof, wherein

M is selected from the group consisting of hydrogen, a pharmaceutically acceptable cation, and a pharmaceutically acceptable metabolically cleavable group;

R₁ and R₂ are independently selected from the group consisting of: hydrogen and C₁₋₆ straight or branched chain alkyl;

R₃ and R₄ are independently selected from the group consisting of C₁₋₁₄ straight or branched chain alkyl optionally substituted by a group selected from halogen, nitro, hydroxyl, carboxyl and amino, and optionally interrupted by -O-, -S(O)₀₋₂-, -NR- wherein R is as defined below, or -CO-; and arylalkyl wherein the alkyl group is straight or branched chain and has from one to eight carbon atoms and the aryl group is phenyl optionally substituted with one or more substituents selected from the group consisting of C₁₋₆ straight or branched chain alkyl and halogen;

A is selected from the group consisting of:


(a) phenylene optionally substituted with one or more substituents selected from the group consisting of C₁₋₆ straight or branched chain alkyl and halogen;

(b) C₃₋₈ cycloalkylene;

(c) C₁₋₁₂ straight or branched chain alkylene;


(d) naphthalene optionally substituted with one or more substituents selected from the group consisting of C₁₋₆ straight or branched chain alkyl and halogen;

(e)



wherein each R₅ and R₆ is independently selected from the group consisting of hydrogen and C₁₋₃ straight or branched chain alkyl; and

5 (f)



wherein

each R₇ and R₈ is independently selected from the group consisting of hydrogen, 10 C₁₋₃ straight or branched chain alkyl, C₁₋₃ straight or branched chain alkoxy, and halogen; m is 1 or 2;

n is 1 or 2; and

B is selected from the group consisting of

- (i) a carbon-carbon bond,
- 15 (ii) oxy,
- (iii) thio,
- (iv) sulfone,
- (v) carbonyl,
- (vi)




20

wherein R is selected from the group consisting of hydrogen and C₁₋₃ straight or branched chain alkyl,

- (vii) —(CH₂)_p— wherein p is an integer from 1 to 14, and

(viii)



5 wherein R₉ and R₁₀ are independently selected from the group consisting of
hydrogen, C₁₋₃ straight or branched chain alkyl, C₃₋₆ cycloalkyl, and
trifluoromethyl.

10 19. A method according to Claim 18, wherein the condition responsive to the
inhibition of the enzyme 5-lipoxygenase is selected from the group consisting of adult
respiratory distress syndrome, allergic rhinitis, arthritis, asthma, cancer, chronic
obstructive pulmonary disease, gout, inflammatory bowel disease, ischemic induced
myocardial injury, psoriasis, reperfusion injury, spinal cord injury, stroke, and traumatic
brain injury.

15 20. A method according to Claim 18, wherein the condition responsive to the
inhibition of the enzyme 5-lipoxygenase is an inflammatory disease.

21. A method according to Claim 18, wherein the condition responsive to the
inhibition of the enzyme 5-lipoxygenase is asthma.

20

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 98/25163

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07C275/64 A61K31/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 11 29 151 B (BASF) 10 May 1962 see examples 3,4 ---	1
A	GB 2 191 194 A (SQUIBB & SONS INC) 9 December 1987 see the whole document ---	1
A	US 5 516 789 A (BROOKS CLINT D W ET AL) 14 May 1996 see the whole document ---	1
A	WO 95 05360 A (PFIZER PHARMA ;KAWAI AKIYOSHI (JP); STEVENS RODNEY W (JP); PFIZER) 23 February 1995 see the whole document -----	1

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

5 March 1999

12/03/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 851 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Goetz, G

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/25163

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 1129151 B			NONE
GB 2191194 A	09-12-1987	US 4728670 A CA 1292005 A DE 3718450 A FR 2599739 A JP 8002858 B JP 62294650 A	01-03-1988 12-11-1991 10-12-1987 11-12-1987 17-01-1996 22-12-1987
US 5516789 A	14-05-1996	WO 9632377 A	17-10-1996
WO 9505360 A	23-02-1995	AT 171939 T AU 674776 B AU 7350994 A BR 9407314 A CA 2169066 A CN 1129440 A CZ 9600483 A DE 69413831 D DE 69413831 T EP 0720598 A ES 2121218 T FI 943799 A JP 2794343 B JP 8511031 T NO 960631 A NZ 269849 A PL 313037 A US 5792882 A ZA 9406253 A	15-10-1998 09-01-1997 14-03-1995 16-04-1996 23-02-1995 21-08-1996 17-07-1996 12-11-1998 25-02-1999 10-07-1996 16-11-1998 20-02-1995 03-09-1998 19-11-1996 16-02-1996 24-10-1997 27-05-1996 11-08-1998 19-02-1996